<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053287</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1902</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-1902</secondary_id>
    <secondary_id>CELGENE-CWRU-1902</secondary_id>
    <secondary_id>CASE-1902</secondary_id>
    <nct_id>NCT00053287</nct_id>
  </id_info>
  <brief_title>Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS</brief_title>
  <official_title>Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping&#xD;
      blood flow to the tumor. Combining chemotherapy with thalidomide may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining fludarabine, carboplatin, and&#xD;
      topotecan with thalidomide in treating patients who have relapsed or refractory acute myeloid&#xD;
      leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate of patients with relapsed/refractory or high-risk acute&#xD;
           myeloid leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes&#xD;
           treated with fludarabine, carboplatin, topotecan, and thalidomide.&#xD;
&#xD;
        -  Determine the non-hematologic toxicity profile and time to hematopoietic recovery in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the effects of this regimen on changes in biologic parameters that may predict&#xD;
           response in these patients.&#xD;
&#xD;
        -  Correlate bone marrow microvascular density before and after treatment with response in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the prognostic value of pretreatment plasma and serum levels of vascular&#xD;
           endothelial growth factor (VEGF) and/or the modulation of serum levels of VEGF during&#xD;
           treatment in predicting response in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to diagnosis (previously untreated acute leukemia&#xD;
      vs other).&#xD;
&#xD;
      Patients receive fludarabine IV over 5-10 minutes and carboplatin IV over 24 hours on days&#xD;
      1-5 followed by topotecan IV continuously over 72 hours. Patients receive oral thalidomide&#xD;
      daily beginning within days 1-3 and continuing in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients with residual disease on day 16-18 may receive a second course of chemotherapy as&#xD;
      above. Patients who achieve remission may receive a third course of chemotherapy as above as&#xD;
      consolidation beginning 4-8 weeks after completion of prior chemotherapy.&#xD;
&#xD;
      Patients are followed monthly for 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients (20 per stratum) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>6 weeks after treatment</time_frame>
  </primary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Carboplatin IV over 24 hours on days 1-5</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Fludarabine IV over 5-10 minutes on days 1-5.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Topotecan IV continuously over 72 hours.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Previously untreated and not a candidate for anthracycline-based&#xD;
                       chemotherapy&#xD;
&#xD;
                    -  In first or second relapse or refractory&#xD;
&#xD;
                    -  Secondary to chemotherapy or an antecedent hematologic disorder and treated&#xD;
                       with no more than 1 prior intensive induction regimen&#xD;
&#xD;
               -  Chronic myelogenous leukemia in blast crisis at diagnosis or after prior imatinib&#xD;
                  mesylate&#xD;
&#xD;
               -  Myelodysplastic syndromes (MDS)&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB) or RAEB in transformation&#xD;
&#xD;
                    -  Must meet at least 1 of the following criteria:&#xD;
&#xD;
                         -  Absolute neutrophil count no greater than 500/mm^3&#xD;
&#xD;
                         -  Platelet or red cell transfusion-dependent after no more than 1 prior&#xD;
                            intensive induction chemotherapy&#xD;
&#xD;
               -  Acute promyelocytic leukemia&#xD;
&#xD;
                    -  t(15, 17)&#xD;
&#xD;
                    -  Failed prior treatment with tretinoin and arsenic&#xD;
&#xD;
               -  Relapsed disease at least 3 months after prior autologous stem cell&#xD;
                  transplantation&#xD;
&#xD;
          -  No active CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT less than 3 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction at least 40%&#xD;
&#xD;
          -  No poorly controlled cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No poorly controlled pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use 1 highly effective and 1 additional method of&#xD;
             contraception for 4 weeks before, during, and for at least 4 weeks after study&#xD;
&#xD;
          -  Male patients must use effective contraception during and for 4 weeks after study&#xD;
&#xD;
          -  Willing and able to comply with the System for Thalidomide Education and Prescribing&#xD;
             Safety (STEPS) program&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No poorly controlled infection&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  No severe peripheral neuropathy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior thalidomide allowed for MDS&#xD;
&#xD;
          -  At least 5 days since prior hematopoietic growth factors&#xD;
&#xD;
          -  At least 2 weeks since prior biologic therapy&#xD;
&#xD;
          -  No prior allogeneic bone marrow transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 24 hours since prior hydroxyurea&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 24 hours since prior corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior cytotoxic anticancer therapy&#xD;
&#xD;
          -  Prior amifostine allowed for MDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda W. Cooper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Brenda Cooper, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

